Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

/PRNewswire/ -- Nanoscope Therapeutics Inc., today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE...

Related Keywords

Dallas ,Texas ,United States , ,Nanoscope Therapeutics Inc ,Drug Administration ,Prnewswire Nanoscope Therapeutics Inc ,Therapeutics Inc ,Multi Characteristic Opsin ,Multi Luminancey Mobility Test ,Multi Luminance Shape Discrimination Test ,Best Corrected Visual Acuity ,About Retinitis ,Retinal Ganglion Cells ,Nanoscope Therapeutics ,